Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Human pegivirus-1 associated leukoencephalitis: Clinical and molecular features.

Balcom EF, Doan MAL, Branton WG, Jovel J, Blevins G, Edguer B, Hobman TC, Yacyshyn E, Emery D, Box A, van Landeghem FKH, Power C.

Ann Neurol. 2018 Sep 24. doi: 10.1002/ana.25343. [Epub ahead of print]

PMID:
30246885
2.

Discriminative analysis of regional evolution of iron and myelin/calcium in deep gray matter of multiple sclerosis and healthy subjects.

Elkady AM, Cobzas D, Sun H, Blevins G, Wilman AH.

J Magn Reson Imaging. 2018 Mar 14. doi: 10.1002/jmri.26004. [Epub ahead of print]

PMID:
29537720
3.

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod.

Nakhaei-Nejad M, Barilla D, Lee CH, Blevins G, Giuliani F.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 28;5(2):e432. doi: 10.1212/NXI.0000000000000432. eCollection 2018 Mar. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2018 Jan 31;5(2):e445.

4.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.

Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team.

N Engl J Med. 2017 Jun 1;376(22):2122-2133. doi: 10.1056/NEJMoa1608889.

5.

Progressive iron accumulation across multiple sclerosis phenotypes revealed by sparse classification of deep gray matter.

Elkady AM, Cobzas D, Sun H, Blevins G, Wilman AH.

J Magn Reson Imaging. 2017 Nov;46(5):1464-1473. doi: 10.1002/jmri.25682. Epub 2017 Mar 16.

PMID:
28301067
6.

Cognitive Implications of Deep Gray Matter Iron in Multiple Sclerosis.

Fujiwara E, Kmech JA, Cobzas D, Sun H, Seres P, Blevins G, Wilman AH.

AJNR Am J Neuroradiol. 2017 May;38(5):942-948. doi: 10.3174/ajnr.A5109. Epub 2017 Feb 23.

7.

Recovery of accurate T2 from historical 1.5 tesla proton density and T2-weighted images: Application to 7-year T2 changes in multiple sclerosis brain.

Uddin MN, McPhee KC, Blevins G, Wilman AH.

Magn Reson Imaging. 2017 Apr;37:21-26. doi: 10.1016/j.mri.2016.11.007. Epub 2016 Nov 14.

PMID:
27856398
8.

Multifocal inflammatory demyelination in a patient with rheumatoid arthritis and treatment complications.

Lu JQ, Ringrose J, Gross D, Emery D, Blevins G, Power C.

J Neurol Sci. 2016 Aug 15;367:305-7. doi: 10.1016/j.jns.2016.06.034. Epub 2016 Jun 16.

PMID:
27423608
9.

Medical Tourism for CCSVI Procedures in People with Multiple Sclerosis: An Observational Study.

Metz LM, Greenfield J, Marrie RA, Jette N, Blevins G, Svenson LW, Alikhani K, Wall W, Dhaliwal R, Suchowersky O.

Can J Neurol Sci. 2016 May;43(3):360-7. doi: 10.1017/cjn.2015.350. Epub 2016 Feb 4.

PMID:
26891024
10.

Neuroinflammation Preceding and Accompanying Primary Central Nervous System Lymphoma: Case Study and Literature Review.

Lu JQ, O'Kelly C, Girgis S, Emery D, Power C, Blevins G.

World Neurosurg. 2016 Apr;88:692.e1-8. doi: 10.1016/j.wneu.2015.11.099. Epub 2015 Dec 24. Review.

PMID:
26724610
11.

Rapid Multifocal Neurologic Decline in an Immunocompromised Patient.

Kromm JA, Power C, Blevins G, Larratt L, van Landeghem FK, Rempel J.

JAMA Neurol. 2016 Feb;73(2):226-31. doi: 10.1001/jamaneurol.2015.2658.

PMID:
26658958
12.

Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.

Uddin MN, Lebel RM, Seres P, Blevins G, Wilman AH.

Mult Scler. 2016 Aug;22(9):1133-43. doi: 10.1177/1352458515614091. Epub 2015 Oct 26.

PMID:
26503237
13.

Association of Factor V Secretion with Protein Kinase B Signaling in Platelets from Horses with Atypical Equine Thrombasthenia.

Norris JW, Pombo M, Shirley E, Blevins G, Tablin F.

J Vet Intern Med. 2015 Sep-Oct;29(5):1387-94. doi: 10.1111/jvim.13595. Epub 2015 Aug 19.

14.

Automated external defibrillator prevalence among the municipal police agencies of New Jersey: how regional differences affect national data.

Pescatore RM, Hong R, Sexton RJ, Carroll GG, Curcio EE, Blevins G, Baumann BM.

Public Health. 2015 Dec;129(12):1652-5. doi: 10.1016/j.puhe.2015.06.009. Epub 2015 Jul 15. No abstract available.

PMID:
26188851
15.

Subcortical gray matter segmentation and voxel-based analysis using transverse relaxation and quantitative susceptibility mapping with application to multiple sclerosis.

Cobzas D, Sun H, Walsh AJ, Lebel RM, Blevins G, Wilman AH.

J Magn Reson Imaging. 2015 Dec;42(6):1601-10. doi: 10.1002/jmri.24951. Epub 2015 May 18.

PMID:
25980643
16.

Decision-making under explicit risk is impaired in multiple sclerosis: relationships with ventricular width and disease disability.

Radomski AD, Power C, Purdon SE, Emery DJ, Blevins G, Warren KG, Fujiwara E.

BMC Neurol. 2015 Apr 23;15:61. doi: 10.1186/s12883-015-0318-0.

17.

Validation of quantitative susceptibility mapping with Perls' iron staining for subcortical gray matter.

Sun H, Walsh AJ, Lebel RM, Blevins G, Catz I, Lu JQ, Johnson ES, Emery DJ, Warren KG, Wilman AH.

Neuroimage. 2015 Jan 15;105:486-92. doi: 10.1016/j.neuroimage.2014.11.010. Epub 2014 Nov 8.

PMID:
25462797
18.

Associations between eating occasion characteristics and age, gender, presence of children and BMI among U.S. adults.

Reicks M, Degeneffe D, Rendahl A, Smith Edge M, Burns K, O'Meara B, Blevins G.

J Am Coll Nutr. 2014;33(4):315-27. doi: 10.1080/07315724.2014.887485. Epub 2014 Aug 20.

PMID:
25140673
19.

The regulation of reactive changes around multiple sclerosis lesions by phosphorylated signal transducer and activator of transcription.

Lu JQ, Power C, Blevins G, Giuliani F, Yong VW.

J Neuropathol Exp Neurol. 2013 Dec;72(12):1135-44. doi: 10.1097/NEN.0000000000000011.

PMID:
24226263
20.

Longitudinal MR imaging of iron in multiple sclerosis: an imaging marker of disease.

Walsh AJ, Blevins G, Lebel RM, Seres P, Emery DJ, Wilman AH.

Radiology. 2014 Jan;270(1):186-96. doi: 10.1148/radiol.13130474. Epub 2013 Oct 28.

PMID:
23925273
21.

MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentary.

Selchen D, Bhan V, Blevins G, Devonshire V, Duquette P, Grand'Maison F, Kremenchutzky M, Lapierre Y, Li D, von Riedemann SJ, Freedman M.

Neurology. 2012 Dec 4;79(23 Suppl 2):S1-15. doi: 10.1212/WNL.0b013e318277d144.

PMID:
23212280
22.

Multiple sclerosis: validation of MR imaging for quantification and detection of iron.

Walsh AJ, Lebel RM, Eissa A, Blevins G, Catz I, Lu JQ, Resch L, Johnson ES, Emery DJ, Warren KG, Wilman AH.

Radiology. 2013 May;267(2):531-42. doi: 10.1148/radiol.12120863. Epub 2013 Jan 7.

PMID:
23297322
23.

Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management.

Dhesi S, Chu MP, Blevins G, Paterson I, Larratt L, Oudit GY, Kim DH.

J Investig Med High Impact Case Rep. 2013 Jan 1;1(1):2324709613480346. doi: 10.1177/2324709613480346. eCollection 2013 Jan-Mar.

24.

Susceptibility phase imaging with improved image contrast using moving window phase gradient fitting and minimal filtering.

Walsh AJ, Eissa A, Blevins G, Wilman AH.

J Magn Reson Imaging. 2012 Dec;36(6):1460-9. doi: 10.1002/jmri.23768. Epub 2012 Aug 3.

PMID:
22865696
25.

Intrathecal effects of daclizumab treatment of multiple sclerosis.

Bielekova B, Richert N, Herman ML, Ohayon J, Waldmann TA, McFarland H, Martin R, Blevins G.

Neurology. 2011 Nov 22;77(21):1877-86. doi: 10.1212/WNL.0b013e318239f7ef. Epub 2011 Nov 9.

26.

Quantitative high-field imaging of sub-cortical gray matter in multiple sclerosis.

Lebel RM, Eissa A, Seres P, Blevins G, Wilman AH.

Mult Scler. 2012 Apr;18(4):433-41. doi: 10.1177/1352458511428464. Epub 2011 Oct 27.

PMID:
22032862
27.

Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.

De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, Gasperini C.

J Neurol Sci. 2012 Jan 15;312(1-2):97-101. doi: 10.1016/j.jns.2011.08.013. Epub 2011 Aug 31.

PMID:
21880336
28.

Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis.

De Stefano N, Curtin F, Stubinski B, Blevins G, Drulovic J, Issard D, Shotekov P, Gasperini C; IMPROVE Study Investigators.

Mult Scler. 2010 Jul;16(7):888-92. doi: 10.1177/1352458510362442. Epub 2010 Mar 3.

PMID:
20200197
29.

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.

Bielekova B, Richert N, Howard T, Packer AN, Blevins G, Ohayon J, McFarland HF, Stürzebecher CS, Martin R.

Mult Scler. 2009 Oct;15(10):1206-14. doi: 10.1177/1352458509345903. Epub 2009 Sep 23.

30.

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Arch Neurol. 2009 Apr;66(4):483-9. doi: 10.1001/archneurol.2009.50.

31.

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, McFarland H, Jacobson S.

Arch Neurol. 2009 Apr;66(4):471-9. doi: 10.1001/archneurol.2009.16.

32.

Neurological picture. Demyelinating butterfly pseudo-glioma.

Scozzafava J, Johnson ES, Blevins G.

J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):12-3. No abstract available.

PMID:
18079298
33.

Platelet function defect in a thoroughbred filly.

Fry MM, Walker NJ, Blevins GM, Magdesian KG, Tablin F.

J Vet Intern Med. 2005 May-Jun;19(3):359-62. No abstract available.

34.

Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation.

Moore DF, Li H, Jeffries N, Wright V, Cooper RA Jr, Elkahloun A, Gelderman MP, Zudaire E, Blevins G, Yu H, Goldin E, Baird AE.

Circulation. 2005 Jan 18;111(2):212-21. Epub 2005 Jan 3.

PMID:
15630028
35.

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Würfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8705-8. Epub 2004 May 25. Erratum in: Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17565.

36.

Impact of a triage tool on air versus ground transport of cardiac patients to a tertiary center.

Werman HA, Jaynes C, Blevins G.

Air Med J. 2004 May-Jun;23(3):40-7.

PMID:
15127044
37.

Future immunotherapies in multiple sclerosis.

Blevins G, Martin R.

Semin Neurol. 2003 Jun;23(2):147-58. Review.

PMID:
12894380
38.

Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His.

Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T, Yazaki M, Hamidi Asl K, Benson MD, Donat JR.

Neurology. 2003 May 27;60(10):1625-30.

PMID:
12771253
39.

Evaluating interfacility ground and air transport of the critical cardiac patient.

Jaynes CL, Blevins G, Werman HA.

Air Med J. 2002 Mar-Apr;21(2):37-41. No abstract available.

PMID:
11896371
40.

Chronic dietary Cu(2+)-deficiency alters cholecystokinin signal transduction in isolated rat pancreatic acini.

Miller ST, McCullough SS, Chowdhury P, Blevins GT Jr.

J Assoc Acad Minor Phys. 2000;11(2-3):21-7.

PMID:
10953540
41.

Response of rat exocrine pancreas to high-fat and high-carbohydrate diets.

Chowdhury P, Nishikawa M, Blevins GW Jr, Rayford PL.

Proc Soc Exp Biol Med. 2000 Mar;223(3):310-5.

PMID:
10719845
42.

Estradiol alters cholecystokinin stimulus-response coupling in rat pancreatic acini.

Blevins GT Jr, McCullough SS, Wilbert TN, Isom RM, Chowdhury P, Miller ST.

Am J Physiol. 1998 Nov;275(5 Pt 1):G993-8.

PMID:
9815029
43.

Effects of diversion and reperfusion of pancreaticobiliary juice on amylase release from isolated rat pancreas.

Nishikawa M, Chowdhury P, Takaori K, Blevins GT Jr, Rayford PL.

J Assoc Acad Minor Phys. 1998;9(2):26-30.

PMID:
9648422
44.

Nucleotides regulate the binding affinity of the recombinant type A cholecystokinin receptor in CHO K1 cells.

Blevins GT, van de Westerlo EM, Logsdon CD, Blevins PM, Williams JA.

Regul Pept. 1996 Feb 22;61(2):87-93.

PMID:
8852809
45.

Effects of diet on cholecystokinin-stimulated amylase secretion by pancreatic Acini and amylase mRNA levels in rat pancreas.

Takaori K, Blevins GT Jr, Nishikawa M, Chowdhury P, Rayford PL.

Pancreas. 1995 Nov;11(4):402-7.

PMID:
8532658
46.

Microglia in colony-stimulating factor 1-deficient op/op mice.

Blevins G, Fedoroff S.

J Neurosci Res. 1995 Mar 1;40(4):535-44.

PMID:
7616613
47.

Nucleoside diphosphate kinase associated with rat pancreatic membranes regulates CCK receptor affinity.

Blevins GT Jr, van de Westerlo EM, Williams JA.

Am J Physiol. 1994 Nov;267(5 Pt 1):G866-74.

PMID:
7977749
48.

Characterization of cholecystokininA receptor agonist activity by a family of cholecystokininB receptor antagonists.

Blevins GT Jr, van de Westerlo EM, Yule DI, Williams JA.

J Pharmacol Exp Ther. 1994 Jun;269(3):911-6.

PMID:
7516969
49.

Rat pancreatic nucleoside diphosphate kinase, a novel regulator of cholecystokinin receptor affinity. Cloning and expression.

Blevins GT Jr, van de Westerlo EM, Blevins PM, Williams JA.

Ann N Y Acad Sci. 1994 Mar 23;713:350-2. No abstract available.

50.

Cholecystokinin and regulation of pancreatic acinar cell function.

Williams JA, Blevins GT Jr.

Physiol Rev. 1993 Oct;73(4):701-23. Review. No abstract available.

PMID:
8415924

Supplemental Content

Loading ...
Support Center